MYADM

Across TCGA pan-cancer cohorts, MYADM Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYADM data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MYADM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYADM expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THYM, UCEC, and SKCM are the cancer types where MYADM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	OS	Median	All	1.000	0.655	.005	24	view →
SKCM	DFS	Median	III,IV	1.000	0.247	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYADM–THYM (OS)

Open the THYM breakdown →